Generic Neurontin Tablets Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpharma and Teva have launched generics for the two highest doses of Pfizer's epilepsy agent Neurontin
You may also be interested in...
Teva/Ranbaxy Launch First Generic Of Pfizer’s Accupril
Teva, which relinquished 180-day exclusivity, is marketing quinapril manufactured under Ranbaxy’s ANDA pursuant to a supply and distribution agreement. Teva/Ranbaxy’s product gets a jump on at least five other potential generic competitors; timing of the generic’s launch may have been earlier than expected by Pfizer.
Teva/Ranbaxy Launch First Generic Of Pfizer’s Accupril
Teva, which relinquished 180-day exclusivity, is marketing quinapril manufactured under Ranbaxy’s ANDA pursuant to a supply and distribution agreement. Teva/Ranbaxy’s product gets a jump on at least five other potential generic competitors; timing of the generic’s launch may have been earlier than expected by Pfizer.
Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.